The expansion will feature state-of-the-art fragment-based peptide synthesis capabilities with multiple 1000 L to 3000 L solid-phase and liquid-phase peptide synthesis equipment lines. Once completed, the new space will add significant manufacturing capacity, with the ability to produce over 8 metric tons of crude peptide annually. This output will be further processed utilizing existing downstream peptide purification and isolation capabilities already available at the Shanghai site and to a greater extent at Ambiopharm’s US manufacturing site in North Augusta, South Carolina.

“This expansion underscores our commitment to China and its role in our global operations”, said Brian Gregg, CEO of Ambiopharm. “Our new capabilities will allow us to meet the growing demand for therapeutic peptides and enhance our ability to serve customers throughout the world.”

The new manufacturing capacity is expected to be operational in the second half of 2025.